期刊文献+

非清髓性异基因骨髓移植治疗白血病的动物实验研究

Experimental Study on Non-myeloablative Allogeneic Bone Marrow Transplantation for Treatment of Leukemia Mice
暂未订购
导出
摘要 [目的]探讨非清髓性异基因骨髓移植及加供者淋巴细胞输注治疗小鼠白血病的疗效。[方法]荷L7212白血病的615(H鄄2K)小鼠,于接种白血病细胞后第2天接受60Co鄄γ射线全身照射(TBI8.5Gy或5Gy)分为若干组,照射当天移植供鼠BALB/C(H鄄2d)小鼠的骨髓细胞(5×106)和脾细胞(1.5×107),移植后第2天腹腔注射环磷酰胺(200mg/kg);供者淋巴细胞输注组分别于移植后第7天、14天、21天再次输注供鼠脾细胞5×106、1×107、2×107,观察受鼠的移植物植入、移植物抗宿主病(GVHD)、受鼠生存时间及移植相关并发症等。[结果]非清髓性预处理能保证移植物的稳定植入,非清髓性异基因骨髓移植组小鼠生存时间为22.3±4.8天,与非清髓空白组14.7±3.4天和传统移植组18.3±3.2天比较均有显著性差异(P<0.05),供者淋巴细胞输注(DLI)组小鼠平均生存时间明显延长,为34.3±2.5天,与非清髓移植组比较均有显著性差异(P<0.05),且无明显GVHD表现和病理学改变,移植相关并发症减少。[结论]非清髓性异基因骨髓移植能在减轻GVHD的同时保留一定的移植物抗白血病(GVL)效应,移植后行DLI可在减轻移植相关并发症的基础上进一步增强GVL效应。 To explore the curative effects of non-myeloablative allogeneic bone marrow transplantation for treatment of leukemia mice. Six hundred and fifteen (H-2K) mice were loaded with L7212 cells and 2 days later underwent total body irradiation(TBI) 8.5 or 5Gy(60Co γ-ray) followed by allogeneic bone marrow transplantation(allo-BMT). The allografts consisted of 5×106 bone marrow cells mixed 1.5×107 spleen cells from BALB/C (H-2d) donor mice. Two days after allo-BMT, the recipient mice were given 200mg/kg of CTX. Afterwards mice of donor lymphocyte infusions(DLI) group received 5×106, 1×107, 2×107 spleen cells from donor mice. The engrafment of allograft, graft versus host disease(GVHD), the survival days and transplantation-related complications were observed. The nonmyeloablative conditioning could ensured the engraftment of allograft, the survival days of mice in nonmyeloablative allo-BMT group were 22.3±4.8, which was much longer than that of nonmyeloablative blank group 14.7±3.4 and myeloablative group 18.3±3.2(P<0.05). There was difference between survival days of mice in DLI group and nonmyeloablative allo-BMT group (P<0.05). The mice in DLI group had no obvious GVHD signs and histological changes. Furthermore the transplantation-related complications had reduced. [Conclusions] The potential GVL effects can be preserved in nonmyeloablative while the degree of GVHD is reduced, and the method of DLI after BMT can reinforce graft versus leukemia(GVL) effects while reduce transplantation-related complications.
出处 《肿瘤学杂志》 CAS 2004年第6期382-385,共4页 Journal of Chinese Oncology
关键词 非清髓性异基因骨髓移植 移植物抗宿主病 移植物抗白血病效应 供者淋巴细胞输注 non-myeloablative bone marrow transplantation graft-versus-host disease graft-versus-leukemia effect donor lymphocyte infusions
  • 相关文献

参考文献2

二级参考文献19

  • 1Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 1998,92:4150-4166.
  • 2Ratajczak M Z, Ratajczak J, Machalinski B, et al. Role of vascular endothelial growth factor(VEGF) and placenta-derived growth factor (PDGF) in regulating human haemopoietic cell growth. British Journal of Haematology, 1998, 103,969-979.
  • 3Gerber H P, Malik A K, Solar G P, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature, 2002, 417 : 954- 958.
  • 4Broxmeyer H E, cooper S, Li Z H, et al. Myeloid progenitor cell regulatorg effects of vascular endothelial cell growth factor. International Journal of Hematology,1995, 62:203-215.
  • 5Melter M, Reinders M E J, Sho M, et al. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial ceils and monocytes and promotes angiogenesis in vivo. Blood, 2000, 96:3801-3808.
  • 6Bautz F, Rafii S, kanz L, et al. Expression and secretion of VEGF-A by cytokine-stimulated hematopoietic progenitor cells: possible role in the hematopoietic microenvironment. Exp Hematol, 2000, 28 : 700- 706.
  • 7Tordjman R, Ortega N, Coulombel L, et al. Neuropi lin-1 is expressed on bone marrow stromal cells: a novel interaction with hematopoietic cells? Blood, 1999, 94:2301-2309.
  • 8Gleichmann E, Gleichmann H, Wilke W, et al. Autoimmunization and lymphoma genesis in parent to F1 combination differing at the major histocompa-tibility complex: model for spontaneous disease caused by altered self-antigens? Transplant Rev, 1976; 31:156
  • 9Or R, Weiss L, Amir G, et al. The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models. Bone Marrow Transplantation, 2000; 25:263 - 266
  • 10Slavin S. New strategies for bone marrow transplantation, Curr Opin Immunol, 2000; 12:542- 551

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部